The present investigation describes a formulative study for the development of innovative drug delivery systems for bromocriptine (BK). Solid lipid nanoparticles (SLN) encapsulation may represent a novel strategy to obtain stable plasmatic levels and increase drug half-life. To prove this hypothesis, SLN have been produced and characterized. The influence of different experimental protocols and lipidic composition on nanoparticle morphology, dimensional distribution and inner structure has been investigated. In vitro release kinetics of BK from SLN have also been evaluated by means of a dialysis method. Finally, the symptomatic effect of the most appropriate BK formulation has been evaluated comparing the effects of free and SLN-encapsulated BK in the best characterized model of PD.
Nanostructured lipid carriers as delivery systems for parkinson’s therapy
ESPOSITO, Elisabetta;FANTIN, Martina;MARTI, Matteo;MENEGATTI, Enea;MORARI, Michele;CORTESI, Rita
2008
Abstract
The present investigation describes a formulative study for the development of innovative drug delivery systems for bromocriptine (BK). Solid lipid nanoparticles (SLN) encapsulation may represent a novel strategy to obtain stable plasmatic levels and increase drug half-life. To prove this hypothesis, SLN have been produced and characterized. The influence of different experimental protocols and lipidic composition on nanoparticle morphology, dimensional distribution and inner structure has been investigated. In vitro release kinetics of BK from SLN have also been evaluated by means of a dialysis method. Finally, the symptomatic effect of the most appropriate BK formulation has been evaluated comparing the effects of free and SLN-encapsulated BK in the best characterized model of PD.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
